<i>In Vitro</i> Activity of Two Cefepime-Based Novel Combinations, Cefepime/Taniborbactam and Cefepime/Zidebactam, against Carbapenemase-Expressing <i>Enterobacterales</i> Collected in India
Yamuna Devi Bakthavatchalam, Divyaa Elangovan, Subha Vajjiravelu Jaganathan, Nivedhana Subburaju, Abirami Shankar, Yuvasri Manokaran, J Sudarsana, Rema Devi, Sujata Baveja, Sheela Devi, S. Jayakumar, Sanjay Bhattacharya, Shoorashetty Manohara Rudresh, Bineshlal Yesudhason, Vignesh Shetty, Ankur Mutreja, Abi Manesh, George M. Varghese, Charis Marwick, Benjamin J. Parcell, Ian H. Gilbert, Balaji Veeraraghavan
Abstract
The study revealed the differential ability of cefepime/taniborbactam and cefepime/zidebactam in tackling carbapenemase-producing Indian clinical isolates that also harbored additional mechanisms of resistance. NDM-expressing E. coli with 4-amino-acid insert in PBP3 are predominately resistant to cefepime/taniborbactam, while the β-lactam enhancer mechanism-based cefepime/zidebactam showed consistent activity against single- or dual-carbapenemase-producing isolates including E. coli with PBP3 inserts.